micro-community-banner
Profile Image
  • Saved
C3G and Ig-MPGN-treatment standard

C3G and Ig-MPGN-treatment standard

Source : https://pubmed.ncbi.nlm.nih.gov/37604793/

Among the broad spectrum of membranoproliferative glomerulonephritis (MPGN), immunofluorescence distinguishes C3 glomerulopathy (C3G), with predominant C3 deposits, and immunoglobulin-associated MPGN (Ig-MPGN), with combined C3 and Ig. However, there are several...

Accurate diagnosis and targeted therapies for primary C3G and Ig-MPGN may improve outcomes through unsupervised clustering analysis and ongoing complement cascade-targeting trials.

Profile Image
  • Saved
Traditional and novel non-statin lipid-lowering drugs

Traditional and novel non-statin lipid-lowering drugs

Source : https://pubmed.ncbi.nlm.nih.gov/37979722/

Non-statin drugs find utility in the management of dyslipidaemia in mixed dyslipidaemia, patients with statin intolerance, and when guidelines directed low-density lipoprotein cholesterol (LDL-C) target cannot be achieved despite maximally...

Non-statin drugs are crucial for managing dyslipidaemia in specific patient groups, especially when LDL-C targets are unachievable with statins alone or in cases of statin intolerance.

Profile Image
  • Saved
Effects of Dietary Carbohydrate Concentration and Glycemic Index on Blood Glucose Variability and Free Fatty Acids in Individuals with Type 1 Diabetes

Effects of Dietary Carbohydrate Concentration and Glycemic Index on Blood Glucose Variability and Free Fatty Acids in Individuals with Type 1 Diabetes

Source : https://pubmed.ncbi.nlm.nih.gov/38732629/

Monitoring glycemic control status is the cornerstone of diabetes management. This study aimed to reveal whether moderate-carbohydrate (CHO) diets increase the risk of free fatty acid (FFA) levels, and it...

In type 1 diabetes, moderate-carbohydrate diets, regardless of glycemic index, did not significantly impact glycemic control but increased free fatty acid and triglyceride levels, potentially elevating cardiovascular risk.

Profile Image
  • Saved
Modulating the Gut Microbiota and Metabolites with Traditional Chinese Medicines: An Emerging Therapy for Type 2 Diabetes Mellitus and Its Complications

Modulating the Gut Microbiota and Metabolites with Traditional Chinese Medicines: An Emerging Therapy for Type 2 Diabetes Mellitus and Its Complications

Source : https://pubmed.ncbi.nlm.nih.gov/38930814/

Currently, an estimated 537 million individuals are affected by type 2 diabetes mellitus (T2DM), the occurrence of which is invariably associated with complications. Glucose-lowering therapy remains the main treatment for...

Traditional Chinese medicines (TCMs) modulate gut microbiota, restoring host homeostasis and ameliorating metabolic disorders, offering a promising approach for managing type 2 diabetes mellitus and its complications with fewer adverse effects.

Profile Image
  • Saved
Comparing the Efficacy of Digital and In-Person Weight Loss Interventions for Patients with Obesity and Glycemic Disorders: Evidence from a Randomized Non-Inferiority Trial

Comparing the Efficacy of Digital and In-Person Weight Loss Interventions for Patients with Obesity and Glycemic Disorders: Evidence from a Randomized Non-Inferiority Trial

Source : https://pubmed.ncbi.nlm.nih.gov/38794747/

Digital weight loss interventions present a viable and cost-effective alternative to traditional therapy. However, further evidence is needed to establish the equal effectiveness of both approaches. This randomized controlled non-inferiority...

Vitadio digital therapy is an effective alternative to traditional in-person weight loss programs, demonstrating comparable weight reduction, improved body composition, lipid metabolism, and glycemic control in patients with obesity.

Profile Image